The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker.
(SOURCE) https://www.cnn.com/2023/01/20/health/alzheimers-drug-donanemab-fda-eli-lilly/index.html